The CSL Behring commitment

CSL Behring is a world leader in specialty biopharmaceuticals and is committed to people around the world with rare and serious conditions, such as hereditary angioedema (HAE).

We’re dedicated to making a difference in the HAE community through education, services, and other resources for patients and families affected by the condition.

  • CSL Behring has established the Berinert Expert Network (B.E.N.™), a resource designed to:
    • Assist you in starting Berinert therapy
    • Connect you to the HAE patient community
    • Help you work through insurance issues and questions
    • Give you an opportunity to share your experiences with your peers via the B.E.N. P.A.L.S. patient advocate program
    • Provide peace of mind through CSL Behring’s Assurance and Assistance programs
  • We sponsor AllAboutHAE.com, an online HAE resource with useful information, such as an interactive treatment journal.
  • We are a proud supporter of the US Hereditary Angioedema Association, a nonprofit patient advocacy organization dedicated to expediting U.S. approval of safer and more effective HAE therapies. In addition, the organization provides a wide range of services that include clinical trial placement, physician referrals, education, and individualized patient case management

CSL Behring is also committed to those who are uninsured or underinsured, as well as those who experience a gap in coverage. To learn more about our assistance programs, please visit the Resources and Support section.

Important Safety Information

Berinert®, C1 Esterase Inhibitor (Human), is for the treatment of ongoing, acute attacks of hereditary angioedema (HAE) affecting the abdomen, face or throat in adults and adolescents. The safety and efficacy of Berinert in preventing HAE attacks have not been established.

Do not use Berinert if you have experienced life-threatening allergic reactions or severe hypersensitivity to the product. Immediately report to your physician or an emergency department any signs or symptoms of allergic reactions to Berinert, including hives, chest tightness, wheezing, turning blue, fast heartbeat, and shock. Also report signs and symptoms of thrombosis that occur after infusing: including swelling and pain in the limbs or abdomen, chest pain, shortness of breath, loss of sensation or motor power, or altered consciousness or speech.

Berinert can be self-administered if you have been trained and advised to do so by your healthcare provider. Seek immediate medical attention if an HAE attack has progressed to a point where you will be unable to prepare or administer Berinert.

Call your doctor right away if swelling is not controlled after use of Berinert.

If you self-administer to treat a laryngeal attack, immediately seek medical attention afterward. If you self-administer for an abdominal attack, inform your physician so that other possible causes can be ruled out.

Because Berinert is made from human blood, the risk that it may transmit infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical studies, the most serious adverse reaction reported in subjects who received Berinert was an increased severity of pain associated with HAE. In the placebo-controlled clinical trial, the most common adverse reaction reported more often among subjects who received Berinert than those receiving placebo was dysgeusia (a bad taste in mouth).

Berinert has not been evaluated in pregnant women or nursing mothers; inform your doctor if you are pregnant or are planning to become pregnant, or if you are breastfeeding or plan to breastfeed. The safety and effectiveness of Berinert have not been established in children under 12 or adults over 65 years of age.

Please see full prescribing information for Berinert, including patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.